Parker Lucy A, Jobanputra Kiran, Okello Velephi, Nhlangamandla Mpumelelo, Mazibuko Sikhathele, Kourline Tatiana, Kerschberger Bernhard, Pavlopoulos Elias, Teck Roger
*Médecins sans Frontières, Geneva, Switzerland; †Swaziland National AIDS Programme, Mbabane, Swaziland; ‡Médecins sans Frontières, Nhlangano, Swaziland; and §Médecins sans Frontières, Mbabane, Swaziland.
J Acquir Immune Defic Syndr. 2015 May 1;69(1):e24-30. doi: 10.1097/QAI.0000000000000537.
In January 2013, Swaziland launched a prevention of mother-to-child transmission of HIV (PMTCT) B+ implementation study in rural Shiselweni. We aimed to identify patient and health service determinants of combined antiretroviral therapy (ART) initiation to help guide national implementation of PMTCT B+.
This prospective cohort study uses routine data from registers and patient files in the PMTCT B+ pilot zone and a neighboring health zone where PMTCT A was the standard of care. All HIV-positive women not on combined ART at the first antenatal care visit between January 28, 2013 and December 31, 2013 were included.
399 women from the PMTCT B+ zone and 183 from the PMTCT A zone are included. The overall proportion of women who had not started an antiretroviral intervention before 32 weeks' gestation was lower in the PMTCT A zone (13% vs 25%, P = 0.003), yet a higher proportion women with CD4 <350 initiated combined ART in the PMTCT B+ zone (86% vs 74%, P = 0.032). Within the PMTCT B+ pilot, initiation rates were highly variable between health facilities; while at patient level, ART initiation was significantly higher among women with CD4 <350 compared with CD4 >350 (80% vs 59%, P < 0.001). Among women with CD4 <350, those recorded as newly diagnosed were more likely to initiate combined ART. Although lower educational level and occupational barriers seemed to hinder combined ART initiation among women with CD4 >350, high proportions of missing socio-demographic data made it impossible to make any firm conclusions to this respect.
This study not only demonstrates challenges in initiating pregnant women on ART, but also identifies opportunities offered by PMTCT B+ for improving treatment initiation among women with lower CD4 counts.
2013年1月,斯威士兰在希塞尔韦尼农村地区开展了一项预防艾滋病母婴传播(PMTCT)B+实施研究。我们旨在确定联合抗逆转录病毒疗法(ART)启动的患者和卫生服务决定因素,以帮助指导全国范围内PMTCT B+的实施。
这项前瞻性队列研究使用了PMTCT B+试验区和以PMTCT A作为标准治疗方案的邻近卫生区登记册和患者档案中的常规数据。纳入了2013年1月28日至2013年12月31日期间首次产前检查时未接受联合ART治疗的所有HIV阳性女性。
纳入了来自PMTCT B+区的399名女性和来自PMTCT A区的183名女性。在PMTCT A区,妊娠32周前未开始抗逆转录病毒干预的女性总体比例较低(13%对25%,P = 0.003),然而,CD4<350的女性中,在PMTCT B+区启动联合ART的比例更高(86%对74%,P = 0.032)。在PMTCT B+试验区内,各医疗机构之间的启动率差异很大;而在患者层面,CD4<350的女性中ART启动率显著高于CD4>350的女性(80%对59%,P<0.001)。在CD4<350的女性中,那些记录为新诊断的女性更有可能启动联合ART。尽管较低的教育水平和职业障碍似乎阻碍了CD4>350的女性启动联合ART,但大量缺失的社会人口统计学数据使得无法就此方面得出任何确凿结论。
本研究不仅证明了孕妇启动ART存在的挑战,还确定了PMTCT B+为改善CD4计数较低女性的治疗启动提供的机会。